Morgan Stanley raised the firm’s price target on CME Group (CME) to $312 from $303 and keeps an Overweight rating on the shares. The firm is updating its price targets for stocks in the Brokers & Exchanges North America sector under its coverage, the analyst tells investors. The firm believes brokers are poised to benefit from growth due to better visibility around rates paths and continued retail engagement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- Freeport-McMoRan, Biogen, Intel, Uranium Energy, CME Trending by Analysts
- Early notable gainers among liquid option names on September 25th
- CME Group price target raised to $252 from $246 at JPMorgan
- Citi upgrades CME Group to Buy on near-term catalysts
- CME Group upgraded to Buy from Neutral at Citi